Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

NCT03610490 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03610490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
October 16, 2018
Completion date
August 21, 2024
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid neoplasm, metastatic colorectal adenocarcinoma, metastatic ovarian carcinoma, metastatic pancreatic ductal adenocarcinoma, platinum-resistant ovarian carcinoma, recurrent high grade ovarian serous adenocarcinoma, recurrent ovarian carcinosarcoma, refractory colorectal carcinoma, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8